// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Hypertension, bone marrow lesions and osteoarthritis (OA

D. Felson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Knee osteoarthritis

N/A

Identification of a protein panel useful for the prediction of response to methotrexate in rheumatoid arthritis patients

C. Ruiz-Romero - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Identification of clinical and serological predictive factors of response to rituximabtreatment in systemic lupus erythematosus (SLE patients

H. Sánchez Pérez - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Rituximab

Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis

H. Brunner - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Glucocorticoid

Identifying clinical, psychological and work related factors associated with presenteeism: the international eular-pro at-work productivity study

S. Verstappen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Identifying patients with axial spondyloarthritis by data mining mri radiology reports

E. Reilly - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

N/A

Iga anti-ccp antibodies are detectable in the saliva but not sputum of individuals at-risk of developing rheumatoid arthritis

K. Mankia - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Il-36 axis is an emerging therapeutic target in psoriatic arthritis synovial tissue

M.-A. Boutet - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Imaging characterisation of remission in rheumatoid arthritis

N. Purkayastha - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Imaging the arthritic joint

J. Brewer - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Immunogenicity of biosimilars for rheumatic diseases: an updated review from regulatory documents and confirmatory clinical trials

V. Strand - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of biologic therapy in sjogren’s syndromepatients with overlapping autoimmune diseases or extraglandular manifestations. a systematic review of literature

G.E. Fragoulis - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Certolizumab pegol

Impact of febuxostat on renal function among gout patients with different renal function

T.-T. Chung - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic kidney disease

Sulfinpyrazone

Impact of osteoarthritis on work participation: a systematic review

S Secchi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Impact of residential area on the profile of rheumatoid arthritis patients initiating their first biologic dmard: results from the ontario best practices research initiative (OBRI

R. Joshi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3

J.K. Wallman - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Impact of tnf inhibitors on need for joint replacement in patients with rheumatoid arthritis: a matched cohort analysis of uk biologics registry data

S. Hawley - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Implantable loop recorder can screen for incidental significant arrhythmias in scleroderma, with cardiac mri ecv and troponin biomarker, useful for risk stratification

R. Dumitru - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Implementation and role of modern musculoskeletal imaging in rheumatological practice in europe

P. Mandl - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improving adherence in gout therapy

A. Abhishek - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved